| Sign up to stay up to date on the latest news from novoMEDLINK™ |
|
|
 |
| Indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. See Limitations of Use below. |
|
|
|
| Could your patients benefit from a therapy switch? |
|
|
 |
| Timothy has a long history of managing his severe hemophilia B. |
| After researching his options, he made the switch to Rebinyn®. |
|
|
 |
|
|
| Learn more about what happened when patients switched to Rebinyn® |
See the post-switch change to annual bleed rates (ABR)—
the real-world results of a retrospective, observational study. |
|
|
|
|
|
| Rebinyn® prophylaxis treatment helps stop bleeds before they start.1 |
|
|
|
|
 |
|
| Have you created an account on novoMEDLINK™? |
 |
| Keep up with important information about treatments for rare bleeding disorders. |
| Receive the latest news about rare bleeding disorders from Novo Nordisk. |
| Download, order, and share educational materials for you and your patients. |
|
|
|
|
| Indications and Usage |
| Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B (congenital Factor IX deficiency) for on demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes. |
| Limitations of Use: Rebinyn® is not indicated for immune tolerance induction in patients with hemophilia B. |
| Important Safety Information |
| Warnings and Precautions |
| • |
|
Hypersensitivity Reactions: Allergic-type hypersensitivity reactions, including anaphylaxis, have occurred with Rebinyn®. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic- or anaphylactic-type reactions occur and initiate appropriate treatment. |
|
| • |
|
Inhibitors: The formation of inhibitors (neutralizing antibodies) to Factor IX has occurred following Rebinyn®. If expected plasma factor IX activity levels are not attained, or if bleeding is not controlled as expected with the administered dose, perform an assay that measures Factor IX inhibitor concentration. Monitor all patients using clinical observations and laboratory tests for the development of inhibitors. Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used. |
|
| • |
|
Thrombotic Events: The use of Factor IX-containing products has been associated with thromboembolic complications. Monitor for thrombotic and consumptive coagulopathy when administering Rebinyn® to patients with liver disease, post-operatively, to newborn infants, or to patients at risk of thrombosis or disseminated intravascular coagulation (DIC). |
|
| • |
|
Nephrotic Syndrome: Nephrotic syndrome has been reported following immune tolerance induction therapy with Factor IX products in hemophilia B patients with Factor IX inhibitors, often with a history of allergic reactions to Factor IX. The safety and efficacy of using Rebinyn® for immune tolerance induction have not been established. |
|
| Adverse Reactions |
| • |
|
The most common adverse reactions reported in previously treated patients in clinical trials (≥1%) were itching and injection site reactions. The most common adverse reactions (≥1%) in previously untreated patients reported in clinical trials were rash, FIX inhibitors, hypersensitivity, itching, injection site reaction, and anaphylactic reaction. |
|
| • |
|
Animals administered Rebinyn® showed accumulation of PEG in the choroid plexus, pituitary, circumventricular organs, and cranial motor neurons. The potential clinical implications of these animal findings are unknown. Consider whether the patient is vulnerable to cognitive impairment, such as infants and children who have developing brains, and patients who are cognitively impaired. |
|
| Please click here for Prescribing Information. |
|
|
| 1. |
Rebinyn [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2022. |
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
Rebinyn® is a registered trademark and novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2023 Novo Nordisk All rights reserved. US23REB00003 September 2023 |
 |
|
|
|
